BR112015000051A2 - tratamento de distúrbios inflamatórios da pele - Google Patents

tratamento de distúrbios inflamatórios da pele

Info

Publication number
BR112015000051A2
BR112015000051A2 BR112015000051A BR112015000051A BR112015000051A2 BR 112015000051 A2 BR112015000051 A2 BR 112015000051A2 BR 112015000051 A BR112015000051 A BR 112015000051A BR 112015000051 A BR112015000051 A BR 112015000051A BR 112015000051 A2 BR112015000051 A2 BR 112015000051A2
Authority
BR
Brazil
Prior art keywords
treatment
skin disorders
inflammatory skin
apc
treat
Prior art date
Application number
BR112015000051A
Other languages
English (en)
Inventor
John Jackson Christopher
Xue Meilang
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902874A external-priority patent/AU2012902874A0/en
Application filed by Univ Sydney filed Critical Univ Sydney
Publication of BR112015000051A2 publication Critical patent/BR112015000051A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

resumo tratamento de distúrbios inflamatórios da pele a invenção se refere a métodos de usar uma quantidade eficaz de proteína c ativada (apc) para tratar um indivíduo para um distúrbio de pele que se caracteriza pela presença de queratinócitos hiperproliferativos.
BR112015000051A 2012-07-04 2013-07-04 tratamento de distúrbios inflamatórios da pele BR112015000051A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012902874A AU2012902874A0 (en) 2012-07-04 Treatment of inflammatory skin disorders
PCT/AU2013/000729 WO2014005183A1 (en) 2012-07-04 2013-07-04 Treatment of inflammatory skin disorders

Publications (1)

Publication Number Publication Date
BR112015000051A2 true BR112015000051A2 (pt) 2017-06-27

Family

ID=49881162

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000051A BR112015000051A2 (pt) 2012-07-04 2013-07-04 tratamento de distúrbios inflamatórios da pele

Country Status (13)

Country Link
US (3) US20150150954A1 (pt)
EP (1) EP2869833B1 (pt)
JP (1) JP6273272B2 (pt)
KR (1) KR102068010B1 (pt)
CN (1) CN104394883B (pt)
AU (1) AU2013286812B2 (pt)
BR (1) BR112015000051A2 (pt)
CA (1) CA2877745C (pt)
ES (1) ES2676422T3 (pt)
HK (1) HK1204573A1 (pt)
IN (1) IN2014DN11181A (pt)
RU (1) RU2662564C2 (pt)
WO (1) WO2014005183A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877745C (en) * 2012-07-04 2021-11-30 The University Of Sydney Treatment of inflammatory skin disorders
CA2946032C (en) * 2014-04-16 2022-06-14 Zz Biotech Llc Use of apc analogue for wound healing
PT3137102T (pt) * 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
WO2020000059A1 (en) * 2018-06-28 2020-01-02 Novapep Pty Ltd Inflammatory skin disorder treatment
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
JP2022516607A (ja) * 2018-12-26 2022-03-01 ダイレクト バイオロジクス エルエルシー 皮膚および毛髪障害を治療するための方法および組成物
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT402260B (de) 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
WO1995030429A1 (en) 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
AR015598A1 (es) 1997-04-28 2001-05-16 Lilly Co Eli FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
CA2398929C (en) 2000-02-04 2011-05-31 The Scripps Research Institute Neuroprotective, antithrombotic and anti-flammatory uses of activated protein c (apc)
AU2001232799A1 (en) 2000-02-11 2001-08-20 Eli Lilly And Company Protein c derivatives
AU2001245319A1 (en) 2000-03-28 2001-10-08 Eli Lilly And Company Methods of treating diseases with activated protein c
EP1328622A2 (en) 2000-10-18 2003-07-23 Maxygen Aps Protein c or activated protein c-like molecules
AU2002302192B2 (en) * 2001-06-13 2007-08-16 Zz Biotech Llc Treatment and composition for wound healing
WO2004041296A2 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
SI1477166T1 (sl) 2003-04-28 2006-12-31 Biofrontera Bioscience Gmbh Uporaba riluzola, kombiniranega s primernimi pomoznimi in dodatnimi snovmi, za zdravljenje bolezni,za katere je znacilna hiperproliferacija keratinocitov, se zlasti nevrodermitisa in psoriaze
WO2005007820A2 (en) 2003-07-08 2005-01-27 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
EP1841442A4 (en) * 2005-01-07 2009-12-09 Northern Sydney And Central Co TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
BRPI0613137A2 (pt) 2005-06-24 2010-12-21 Drugrecure Aps administração em vias aéreas de proteìna c ativada em condições inflamatórias afetando o trato respiratório
JP5203196B2 (ja) * 2005-08-04 2013-06-05 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのオキサゾロピリジン誘導体
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
CA2668187A1 (en) 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) * 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
JP2012522762A (ja) * 2009-04-01 2012-09-27 ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター ケラチノサイトの増殖および分化を調節する方法
CN101912450A (zh) * 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
CA2877745C (en) * 2012-07-04 2021-11-30 The University Of Sydney Treatment of inflammatory skin disorders
PT3137102T (pt) 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
CA2946032C (en) * 2014-04-16 2022-06-14 Zz Biotech Llc Use of apc analogue for wound healing
WO2020000059A1 (en) * 2018-06-28 2020-01-02 Novapep Pty Ltd Inflammatory skin disorder treatment

Also Published As

Publication number Publication date
AU2013286812B2 (en) 2017-04-20
KR20150036351A (ko) 2015-04-07
JP6273272B2 (ja) 2018-01-31
CA2877745C (en) 2021-11-30
US11617785B2 (en) 2023-04-04
CN104394883B (zh) 2017-05-31
US20150150954A1 (en) 2015-06-04
CN104394883A (zh) 2015-03-04
RU2015103510A (ru) 2016-08-27
EP2869833A1 (en) 2015-05-13
KR102068010B1 (ko) 2020-01-20
IN2014DN11181A (pt) 2015-10-02
ES2676422T3 (es) 2018-07-19
EP2869833B1 (en) 2018-04-04
US20200276281A1 (en) 2020-09-03
HK1204573A1 (en) 2015-11-27
RU2662564C2 (ru) 2018-07-26
AU2013286812A1 (en) 2015-01-22
CA2877745A1 (en) 2014-01-09
EP2869833A4 (en) 2015-11-18
JP2015521632A (ja) 2015-07-30
WO2014005183A1 (en) 2014-01-09
US20170080062A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
BR112015000051A2 (pt) tratamento de distúrbios inflamatórios da pele
ECSP22051489A (es) Compuestos inhibidores de metaloenzimas
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
ECSP14013153A (es) Compuestos inhibidores de metaloenzimas
CL2016002509A1 (es) Composiciones para modular la expresión de sod-1
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
NI201200120A (es) Derivados de fumarato de ácido graso y sus usos.
IN2014MN01378A (pt)
EA201491817A1 (ru) Терапевтическое применение продуктов из косточек винограда шардоне
UA110813C2 (uk) Лікування ліподистрофії
DK2877184T3 (da) Sammensætninger og behandling for øjensygdomme og -lidelser
IN2014DN06792A (pt)
EA201391248A1 (ru) Биспецифические связывающие агенты
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
DOP2014000253A (es) Inhibidores del nampt
MX2015003701A (es) Composiciones para tratamiento.
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
BR112013024211A2 (pt) tratamento de tumores sólidos
CR20140553A (es) Compuestos de fenoxietil piperidina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ZZ BIOTECH LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]